News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
PACT Enterprise Awards
PCI supported Penn spinouts Interius BioTherapeutics, Verismo Therapeutics, viTToria biotherapeutics, Exyn Technologies, and Avisi Technologies are all nominated for awards.
Mitchell Lab’s Targeted Prenatal Therapy for Mothers and Their Babies Addresses Gap in Health Equity
The researchers’ successful trials in mice show that the technology may potentially lead to promising treatment options for humans with pre-eclampsia.
Penn Medicine, CHOP receive $25M anonymous gift to accelerate research in rare genetic brain disorders
The donation will establish the Center for Epilepsy and Neurodevelopmental Disorders, which will initially focus on developing therapies for disorders related to genetic mutations that are linked to a
Eidos LGBTQ+ Health Initiative Support Advances in LGBTQIA+ Health Startups
The goal of the partnership is to support founders and entrepreneurs with in-depth LGBTQ+ health knowledge and research expertise.
Equimeter Wins $10,000 2023 Penn Y-Prize
The Equimeter team consisted of undergraduates Ujjayi Pamidigantam (Vagelos LSM), Parthiv Patel (Vagelos LSM), and Advait T. (Vagelos LSM)
Nia Therapeutics and Peroxitech Raise Venture Funding
Two Penn spinout companies have recently brought in major investments to help further advance their technologies.
fake troo
Koo and Steager's magnetic, scalable, tether-free robotic devices can be used for diagnostics via retrieval and sampling of biofilms associated with infectious diseases.
PCI Fellows’ Meeting
The PCI Fellows had a lovely potluck at Tomas’s house in January. They shared their latest news, brought great food to share, and even had piano performances by Max and Dora.
Penn Scientists New Research Shows That a CAR-T gel Treatment May Be Able to Kill Residual Cancer Cells Left Over from Surgery
In the study, Penn scientists added CAR-T cells to a gel designed to prevent bleeding after surgery and applied it to the surgical wounds of mice after they had hard-to-treat tumors resected.